Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization
- PMID: 39073760
- PMCID: PMC11426254
- DOI: 10.1093/cid/ciae319
Cytomegalovirus Disease: Fine-Tuning Clinical Trial Enrollment and Standardization
Conflict of interest statement
Potential conflicts of interest. D. v. D. has National Institutes of Health funding unrelated to this work and has received grants from Merck and consulting fees and honoraria from Shionogi, Merck, Union, Roche, Qpex, Pfizer, Entasis, and Clinical Care Options. J. M. C. R. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.Clin Infect Dis. 2024 Sep 26;79(3):787-794. doi: 10.1093/cid/ciae321. Clin Infect Dis. 2024. PMID: 39041385 Free PMC article.
References
-
- Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 2017; 64:87–91. - PubMed
-
- Berengua C, Miró E, Gutiérrez C, et al. Detection of cytomegalovirus in bronchoalveolar lavage fluid from immunocompromised patients with pneumonitis by viral culture and DNA quantification. J Virol Methods 2023; 317:114743. - PubMed
